StreetInsider.com News Articles

Form 8-K Iterum Therapeutics plc For: Mar 30

Tue, 31 Mar 2026 07:00:00 -0400

si-local-file:///var/storage/secattach/20260331/26245089.html

Form 8-K Iterum Therapeutics plc For: Mar 30

Tue, 31 Mar 2026 07:00:00 -0400

si-local-file:///var/storage/secattach/20260331/26245089.html

H.C. Wainwright Downgrades Iterum Therapeutics (ITRM) to Neutral

Mon, 30 Mar 2026 09:49:07 -0400

H.C. Wainwright analyst Matthew Keller downgraded Iterum Therapeutics (NASDAQ: ITRM) from Buy to Neutral.

The analyst comments "We are downgrading to Neutral from Buy and removing our price target. We look to potentially reevaluate our thesis and valuation pending visibility on a path forward for Iterum's program(s) and ability to fund a path forward. Risk factors that could impede the stock include failed or inconclusive clinical trials, the inability of the company to secure adequate funding to progress its drugs through the development pathway or the occurrence of dilutive capital raises, and lack of commercial success."

For an analyst ratings summary and

H.C. Wainwright Downgrades Iterum Therapeutics (ITRM) to Neutral

Mon, 30 Mar 2026 09:49:07 -0400

H.C. Wainwright analyst Matthew Keller downgraded Iterum Therapeutics (NASDAQ: ITRM) from Buy to Neutral.

For an analyst ratings summary and

Iterum Therapeutics files petition to wind up company operations

Fri, 27 Mar 2026 09:25:32 -0400

Iterum Therapeutics plc (NASDAQ: ITRM) filed a petition in Ireland's High Court to wind up the company, according to a statement from the Dublin and Chicago-based pharmaceutical firm. The court appointed Damien Murran and Jennifer McMahon of Teneo Restructuring (Ireland) Limited as Joint Provisional Liquidators.

The petition is scheduled for hearing on April 13, 2026. If approved, the Joint Provisional Liquidators will become Joint Liquidators, leading to the company's dissolution. The liquidators were also appointed to the company's Irish subsidiary, Iterum Therapeutics International Limited.

The company cited several factors in its decision to pursue liquidation, including limited cash resources, inability to raise

Iterum Therapeutics files petition to wind up company operations

Fri, 27 Mar 2026 09:25:32 -0400

The company cited several factors in its decision to pursue liquidation, including limited cash resources, inability to raise

Iterum Therapeutics Announces Filing of Winding Up Petition

Fri, 27 Mar 2026 09:25:00 -0400

DUBLIN and CHICAGO, March 27, 2026 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (in Provisional Liquidation) (Nasdaq: ITRM) (the “Company” or “Iterum” or “we”), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that it has filed a petition in the High Court in Ireland to wind up the Company. An Order was made appointing Damien Murran and Jennifer McMahon, each of Teneo Restructuring (Ireland) Limited (the “Joint Provisional Liquidators”), as Joint Provisional Liquidators to the Company.

The petition is

Iterum Therapeutics Announces Filing of Winding Up Petition

Fri, 27 Mar 2026 09:25:00 -0400

The petition is

Form 8-K Iterum Therapeutics plc For: Mar 27

Fri, 27 Mar 2026 09:21:00 -0400

si-local-file:///var/storage/secattach/20260327/26228872.html

Form 8-K Iterum Therapeutics plc For: Mar 27

Fri, 27 Mar 2026 09:21:00 -0400

si-local-file:///var/storage/secattach/20260327/26228872.html

Maxim Group Downgrades Iterum Therapeutics (ITRM) to Hold

Wed, 04 Mar 2026 07:37:57 -0400

Maxim Group analyst Jason McCarthy downgraded Iterum Therapeutics (NASDAQ: ITRM) from Buy to Hold.

For an analyst ratings summary and ratings history on Iterum Therapeutics click here. For more ratings news on Iterum Therapeutics click here.

Shares of Iterum Therapeutics closed at $0.15 yesterday.

Form 8-K Iterum Therapeutics plc For: Mar 03

Tue, 03 Mar 2026 16:46:00 -0400

si-local-file:///var/storage/secattach/20260303/26102839.html

Form 8-K Iterum Therapeutics plc For: Mar 03

Tue, 03 Mar 2026 16:46:00 -0400

si-local-file:///var/storage/secattach/20260303/26102839.html

Form 8-K Iterum Therapeutics plc For: Feb 24

Mon, 02 Mar 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260302/26093503.html

Form 8-K Iterum Therapeutics plc For: Feb 24

Mon, 02 Mar 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260302/26093503.html

Form 8-K Iterum Therapeutics plc For: Feb 18

Wed, 18 Feb 2026 17:06:00 -0400

si-local-file:///var/storage/secattach/20260218/26023419.html

Form 8-K Iterum Therapeutics plc For: Feb 18

Wed, 18 Feb 2026 17:06:00 -0400

si-local-file:///var/storage/secattach/20260218/26023419.html

Form DEFA14A Iterum Therapeutics plc

Fri, 13 Feb 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260213/26000968.html

Form DEFA14A Iterum Therapeutics plc

Fri, 13 Feb 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260213/26000968.html

Iterum Therapeutics expands ORLYNVAH coverage, receives new patent

Fri, 13 Feb 2026 08:01:06 -0400

Iterum Therapeutics plc (NASDAQ: ITRM) announced a rebate agreement with one of the top three Medicare Part D Pharmacy Benefit Managers, expanding potential coverage for its antibiotic ORLYNVAH to more than 3.5 million lives beginning as early as this quarter.

The Dublin and Chicago-based company received a U.S. patent numbered 12,544,337 covering a bilayer tablet comprising sulopenem etzadroxil and probenecid. The patent, titled "Combinations of Beta-Lactam Compounds and Probenecid and Uses Thereof," is projected to expire in December 2039 and covers methods of treating diseases including uncomplicated urinary tract infections.

The Food and Drug Administration responded to Iterum's request regarding the use

Iterum Therapeutics expands ORLYNVAH coverage, receives new patent

Fri, 13 Feb 2026 08:01:06 -0400

The Food and Drug Administration responded to Iterum's request regarding the use

Iterum Therapeutics Provides Business Update

Fri, 13 Feb 2026 08:00:00 -0400

--Expanded Market Access and Patent Protection for ORLYNVAH™

--FDA correspondence regarding the use of ORLYNVAH™ as step-down therapy

DUBLIN and CHICAGO, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum” or “we”), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today provided a business update.

Recent Events

Market Access Update:
- Medicare Part D Milestone: We are pleased to announce another signed rebate agreement with one of

Iterum Therapeutics Provides Business Update

Fri, 13 Feb 2026 08:00:00 -0400

--Expanded Market Access and Patent Protection for ORLYNVAH™

--FDA correspondence regarding the use of ORLYNVAH™ as step-down therapy

Recent Events

Market Access Update:
- Medicare Part D Milestone: We are pleased to announce another signed rebate agreement with one of

Form DEFA14A Iterum Therapeutics plc

Mon, 26 Jan 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260126/25893735.html

Form DEFA14A Iterum Therapeutics plc

Mon, 26 Jan 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260126/25893735.html